SPCC1442.11c Antibody

What is SPCC1442.11c and what biological role does its protein product play?

SPCC1442.11c is a gene found in Schizosaccharomyces pombe (fission yeast), encoding a protein with the UniProt accession number O94583. Similar to characterized membrane-associated proteins, it likely contains specific domains that contribute to its cellular function. Like other membrane proteins that undergo post-translational modifications, it may contain sites of glycosylation that affect its structure and function . Understanding the biological role of this protein requires comprehensive characterization through various experimental approaches, including knockout studies, localization assays, and interaction analyses.

What are the key technical specifications of SPCC1442.11c Antibody?

SPCC1442.11c Antibody (CSB-PA528473XA01SXV) is likely available in both concentrated (0.1ml) and diluted (2ml) formats, similar to other research antibodies in specialized catalogs . When evaluating this antibody for research, consider these specifications:

When designing experiments, these specifications determine compatibility with experimental conditions and other reagents.

How should researchers validate SPCC1442.11c Antibody specificity?

Validation of antibody specificity is critical for reliable research outcomes. For SPCC1442.11c Antibody, implement these methodological approaches:

• Positive and negative controls: Use samples with known expression levels, including genetic knockouts when available

• Blocking peptide competition: Pre-incubate antibody with purified antigen to confirm signal specificity

• Cross-reactivity testing: Assess binding to related proteins from different species

• Multiple detection methods: Compare results across Western blot, immunoprecipitation, and immunofluorescence

• siRNA knockdown: Verify reduced signal following target gene silencing

Similar to validation procedures for other antibodies, these methods ensure experimental rigor and reproducibility.

What are optimal protocols for using SPCC1442.11c Antibody in Western blotting?

When optimizing Western blot protocols for SPCC1442.11c Antibody, consider the following methodological approach:

• Sample preparation:

  • Extract proteins using buffers containing appropriate protease inhibitors

  • Heat samples at 95°C for 5 minutes in SDS sample buffer

  • Load 20-50 μg of total protein per lane

• Electrophoresis and transfer:

  • Use 10-12% SDS-PAGE gels for optimal separation

  • Transfer to PVDF membranes at 100V for 60-90 minutes

• Blocking and antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST for 1 hour

  • Dilute primary antibody (1:500-1:2000) in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Wash 3x with TBST before secondary antibody incubation

• Detection optimization:

  • Use appropriate HRP-conjugated secondary antibody

  • Consider enhanced chemiluminescence for sensitive detection

Since antibody binding can be divalent cation dependent, as observed with other antibodies like CD11c clone 3.9, ensure buffers contain appropriate ions for optimal binding .

How should researchers optimize immunohistochemistry experiments with SPCC1442.11c Antibody?

For immunohistochemistry applications with SPCC1442.11c Antibody, optimize these critical parameters:

• Fixation method:

  • Test both paraformaldehyde (4%) and acetone fixation

  • Compare results between frozen and paraffin-embedded sections

  • Optimize fixation time (4-24 hours) to preserve epitope accessibility

• Antigen retrieval:

  • Evaluate citrate buffer (pH 6.0) and EDTA buffer (pH 9.0)

  • Test microwave, pressure cooker, and water bath methods

  • Determine optimal retrieval time (10-30 minutes)

• Antibody incubation:

  • Test concentration gradient (1:100 to 1:1000)

  • Compare overnight 4°C vs. room temperature incubation

  • Evaluate different detection systems (HRP/DAB vs. fluorescent)

• Controls:

  • Include isotype controls to assess background staining

  • Use known positive and negative tissue samples

  • Consider peptide competition controls

If working with tissues containing high endogenous peroxidase activity, include appropriate quenching steps before antibody incubation.

What considerations are important when using SPCC1442.11c Antibody in flow cytometry?

When adapting SPCC1442.11c Antibody for flow cytometry, consider these methodological details:

• Sample preparation:

  • For cell lines, use gentle dissociation methods to preserve surface epitopes

  • For primary cells, optimize isolation protocols to maintain viability

  • Test different fixation/permeabilization reagents if target is intracellular

• Antibody titration:

  • Perform serial dilutions (1:50 to 1:500) to determine optimal concentration

  • Calculate signal-to-noise ratio for each concentration

  • Select concentration with highest staining index

• Staining protocol:

  • Incubate 5 μl antibody per million cells in 100 μl staining volume

  • For whole blood samples, use 5 μl per 100 μl blood

  • Incubate 20-30 minutes at room temperature or 4°C

• Buffer considerations:

  • If antibody binding is divalent cation dependent (like some integrins), avoid EDTA in buffers

  • Use heparin rather than EDTA as anti-coagulant for blood samples

  • Include 2% FBS in staining buffer to reduce non-specific binding

• Controls and analysis:

  • Include fluorescence-minus-one (FMO) controls

  • Use appropriate compensation when multiplexing

  • Consider viability dyes to exclude dead cells

How can active learning approaches improve experimental design when working with SPCC1442.11c Antibody?

Active learning methodologies can significantly enhance the efficiency of experiments involving SPCC1442.11c Antibody, particularly when characterizing novel binding interactions. Rather than testing all possible experimental conditions randomly, researchers can employ iterative strategies:

• Initial targeted screening:

  • Begin with a small set of diverse experimental conditions

  • Analyze results to identify promising parameters

  • Use machine learning algorithms to predict optimal conditions

• Iteration and refinement:

  • Select subsequent experimental conditions based on previous results

  • Calculate receiver operating characteristic area under the curve (ROC AUC) to assess improvement

  • Continue iterations until performance plateaus

• Validation against random selection:

  • Compare active learning approach against random selection baseline

  • Evaluate area under the active learning curve (ALC) as performance metric

  • Quantify efficiency improvements in terms of time and resources

This approach has been shown to improve experimental efficiency by up to 30% compared to random sampling strategies when characterizing antibody-antigen interactions .

How can researchers develop antibody combinations incorporating SPCC1442.11c Antibody for enhanced specificity?

Developing effective antibody combinations that include SPCC1442.11c Antibody requires careful epitope mapping and functional testing:

• Epitope mapping:

  • Identify binding regions using peptide arrays or HDX-MS

  • Determine if SPCC1442.11c Antibody binds to conformational or linear epitopes

  • Select additional antibodies targeting non-competing epitopes

• Simultaneous binding assessment:

  • Use techniques like sandwich ELISA to confirm non-competing binding

  • Develop cryo-EM structural models of multi-antibody complexes

  • Verify that antibodies can bind simultaneously without steric hindrance

• Functional validation:

  • Test combinations in relevant assays (e.g., neutralization, signaling)

  • Compare performance of individual antibodies versus combinations

  • Assess whether combinations provide enhanced specificity or sensitivity

• Resistance/escape analysis:

  • Evaluate if combinations prevent development of resistance

  • Test against variant forms of target protein

  • Assess protection against mutations that might affect epitope recognition

Non-competing antibody combinations targeting different epitopes can maintain potency even when individual antibodies lose effectiveness due to target mutations, similar to the strategy employed with REGEN-COV antibody cocktails .

What approaches can be used to determine the three-dimensional binding interface of SPCC1442.11c Antibody with its target?

Elucidating the structural basis of SPCC1442.11c Antibody-antigen interactions requires multiple complementary techniques:

• Cryo-electron microscopy (cryo-EM):

  • Prepare antibody-antigen complexes for imaging

  • Generate 3D reconstructions at sub-nanometer resolution

  • Develop models of binding interfaces and epitope mapping

• X-ray crystallography:

  • Crystallize antibody Fab fragments in complex with target protein

  • Collect diffraction data at synchrotron facilities

  • Solve structure to determine atomic-level interactions

• Computational docking and molecular dynamics:

  • Use homology modeling to predict antibody structure

  • Perform in silico docking to identify potential binding modes

  • Validate predictions through mutagenesis studies

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS):

  • Compare deuterium uptake between free and antibody-bound target

  • Identify regions with altered solvent accessibility upon binding

  • Map epitope regions with peptide-level resolution

• Alanine scanning mutagenesis:

  • Systematically replace residues in the target protein with alanine

  • Measure binding affinity changes for each mutant

  • Identify critical residues for antibody recognition

This multi-technique approach provides comprehensive characterization of binding interfaces, enabling rational optimization of antibody properties.

How should researchers address non-specific binding issues with SPCC1442.11c Antibody?

Non-specific binding is a common challenge when working with antibodies. To troubleshoot these issues with SPCC1442.11c Antibody:

• Optimization of blocking conditions:

  • Test different blocking agents (BSA, casein, non-fat milk) at various concentrations (3-5%)

  • Extend blocking time from 1 hour to overnight at 4°C

  • Include 0.1-0.3% Triton X-100 or Tween-20 in blocking buffer

• Antibody titration and incubation optimization:

  • Test serial dilutions to identify optimal concentration

  • Reduce primary antibody concentration to minimize background

  • Compare room temperature vs. 4°C incubation times

• Sample preparation modifications:

  • Increase wash buffer stringency (higher salt concentration)

  • Pre-absorb antibody with proteins from non-target species

  • Filter lysates to remove aggregates that cause non-specific binding

• Control experiments:

  • Include isotype controls to assess background

  • Perform peptide competition assays

  • Test antibody on samples known to lack the target protein

Document optimization steps systematically in a laboratory notebook to ensure reproducibility once optimal conditions are established.

What are strategies for improving signal-to-noise ratio when using SPCC1442.11c Antibody?

Enhancing signal-to-noise ratio is critical for generating reliable data with SPCC1442.11c Antibody:

• Signal amplification methods:

  • Implement tyramide signal amplification (TSA) for IHC/IF

  • Use enhanced chemiluminescence substrates for Western blots

  • Consider biotin-streptavidin amplification systems

• Noise reduction approaches:

  • Optimize washing steps (increase number, duration, and buffer composition)

  • Reduce autofluorescence with sodium borohydride or Sudan Black B

  • Use low-fluorescence mounting media for microscopy

• Technical optimization:

  • For flow cytometry, adjust photomultiplier tube (PMT) voltages

  • For microscopy, optimize exposure times and gain settings

  • For Western blot, reduce secondary antibody concentration

• Quantitative analysis:

  • Calculate signal-to-noise ratios across different conditions

  • Implement background subtraction algorithms

  • Use internal controls to normalize signals between experiments

When comparing conditions, create a quantitative metric (staining index = [MFI positive - MFI negative] / [2 × SD of negative]) to objectively assess improvements.

How can researchers determine if batch-to-batch variability affects SPCC1442.11c Antibody performance?

Antibody lot-to-lot consistency is critical for experimental reproducibility. To assess and address batch variability:

• Validation protocol development:

  • Establish standardized testing procedures for each new lot

  • Define acceptance criteria based on previous lot performance

  • Create reference samples that can be used across multiple years

• Quantitative comparison metrics:

  • Measure target specificity by Western blot band intensity

  • Compare titration curves between lots

  • Assess staining patterns in validated positive control samples

• Performance tracking:

  • Maintain detailed records of lot numbers used for each experiment

  • Document antibody concentration, age, and storage conditions

  • Track signal intensity and background across experiments

• Mitigation strategies:

  • Purchase larger lots for long-term studies

  • Validate multiple lots simultaneously before original lot depletion

  • Consider developing custom in-house antibodies for critical applications

Implementing a systematic validation approach will ensure experimental continuity and reproducibility across different antibody lots.

What factors should researchers consider when choosing between different antibodies against SPCC1442.11c?

When selecting the optimal SPCC1442.11c Antibody for specific research applications, evaluate these criteria:

• Technical specifications comparison:

  • Clone type (monoclonal vs polyclonal)

  • Host species (compatibility with other reagents)

  • Specific applications validated (WB, IHC, IF, IP, FACS)

  • Epitope location and accessibility

• Validation evidence assessment:

  • Peer-reviewed publication citations

  • Specificity testing methodology

  • Knockout/knockdown validation

  • Cross-reactivity profiles

• Application-specific considerations:

  • For structural studies: epitope location relative to functional domains

  • For functional studies: neutralizing vs. non-neutralizing properties

  • For multiplexing: host species compatibility with other antibodies

  • For in vivo studies: species cross-reactivity and immunogenicity

• Technical support availability:

  • Detailed protocols for specific applications

  • Responsive technical assistance

  • Batch-to-batch consistency controls

  • Custom formulation options

Create a decision matrix with weighted criteria based on your specific experimental requirements to objectively select the optimal antibody.

How can researchers validate cross-reactivity of SPCC1442.11c Antibody with orthologs from different species?

Cross-species reactivity validation is essential for comparative studies across model organisms:

• Sequence analysis approach:

  • Align epitope sequences across species using bioinformatics tools

  • Calculate percent identity and similarity in epitope regions

  • Identify conserved and variable amino acids within binding sites

• Experimental validation methods:

  • Test antibody against recombinant proteins from different species

  • Perform Western blots on lysates from multiple organisms

  • Compare staining patterns in tissues from different species

• Negative control testing:

  • Use knockout/knockdown samples when available

  • Test in species predicted to lack the epitope based on sequence

  • Include appropriate isotype controls for each species

• Quantitative cross-reactivity assessment:

  • Measure relative binding affinity across species

  • Compare EC50 values in ELISA with orthologs from different organisms

  • Develop standard curves for quantification across species

This systematic approach ensures reliable interpretation of results when using SPCC1442.11c Antibody across different model systems.

What criteria should guide the selection of appropriate controls for experiments using SPCC1442.11c Antibody?

Proper experimental controls are critical for interpreting results with SPCC1442.11c Antibody:

• Positive controls:

  • Samples with confirmed target expression

  • Recombinant target protein at known concentrations

  • Cell lines with verified target expression levels

• Negative controls:

  • Genetic knockout or knockdown samples

  • Tissues/cells known to lack target expression

  • Samples from species with confirmed absence of cross-reactivity

• Technical controls:

  • Isotype control antibodies to assess non-specific binding

  • Secondary-only controls to evaluate background

  • Peptide competition controls to confirm specificity

• Loading/normalization controls:

  • Housekeeping proteins for Western blots (β-actin, GAPDH, tubulin)

  • Nuclear markers for microscopy (DAPI, Hoechst)

  • Spike-in controls for quantitative applications

• Process controls:

  • Fresh vs. fixed samples to assess epitope sensitivity

  • Different fixation methods to optimize epitope preservation

  • Storage time controls to evaluate stability

When selecting loading control antibodies, consider tissue-specific expression patterns and experimental conditions to ensure reliable normalization .